PHLI PacificHealth Laboratories Inc (CE)

PacificHealth Laboratories, Inc. (OTCBB: PHLI), a leading sports nutrition company, today reported its financial results for the quarter and six months ended June 30, 2010.

Second Quarter 2010 vs. Second Quarter 2009 Financial Results

Revenues were $2,554,306 compared to $2,725,055 for the same period in 2009. Net income for the second quarter of 2010 increased to $136,725, or $0.01 per diluted share, from net income of $12,922, or $0.00 per diluted share, for the same period in 2009. In the second quarter of 2009, as a result of a change in estimate relating to revenue recognition in connection with sales to a major customer, the Company recognized additional revenues of approximately $279,000. Had the Company not recorded these additional revenues, revenues would have increased $108,251 (or approximately 4%, non-GAAP measure) for the second quarter of 2010 as compared to the same period in 2009. Sales and marketing expenses decreased $105,642, or 23%, in the second quarter of 2010 as compared to the same period in 2009. General and administrative (“G & A”) expenses decreased $84,576, or 10% in the second quarter of 2010 as compared to the same period in 2009. Included in G & A in the second quarter of 2010 and 2009 is approximately $104,000 and $74,000, respectively, paid to former CEO’s in the form of non-compete clauses pursuant to Separation Agreements. Had the Company not incurred these Separation expenses, net income for the second quarter of 2010 would have been approximately $241,000, or $0.02 per share (non-GAAP measure) compared to net income for the second quarter of 2009 of approximately $87,000, or $0.01 per share (non-GAAP measure).

At June 30, 2010, the Company had cash, cash equivalents, and other short-term investments of $757,000 as compared to $426,000 at March 31, 2010 and $456,000 at December 31, 2009.

“Our focus on the core endurance nutrition business is beginning to show positive financial results. We were able to increase shipments in dollars in the quarter by 4%, reflecting increased consumption while continuing to keep our expenses down year over year, resulting in net income growth of over 10 times from a year ago,” said Fred Duffner, President of PacificHealth Laboratories. “We also launched our new single serve sachets beginning in June into the sports specialty channel which we expect to continue to drive trial as well as allow our loyal consumers an easy take along sachet for their endurance activity.”

First Half 2010 Financial Results vs. First Half 2009 Financial Results

Revenue was $4,204,571 compared to $4,420,673 for the same period in 2009. Net loss for the first half of 2010 was $132,505, or $0.01 per diluted share, compared to a net loss of $392,543, or $0.03 per diluted share, for the same period in 2009. In the first six months of 2009, as a result of a change in estimate relating to revenue recognition in connection with sales to a major customer, the Company recognized additional revenues of approximately $279,000. Had the Company not recognized these additional revenues, revenues would have increased $62,898 (or approximately 2%, non-GAAP measure) for the first six months of 2010 as compared to the same period in 2009. Sales and marketing expenses decreased $186,665, or 24%, in the first six months of 2010 as compared to the same period in 2009. General and administrative expenses decreased $142,908, or 9%, in the first six months of 2010 compared to the same period in 2009. Included in G & A in the first six months of 2010 and 2009 is approximately $173,000 and $147,000, respectively, paid to former CEO’s in the form of non-compete clauses pursuant to Separation Agreements. Had the Company not incurred these Separation expenses, the Company would have recorded a net income for the first six months of 2010 of approximately $40,000, or $0.00 per share (non-GAAP measure) compared to a net loss for the six months of 2009 of approximately $246,000, or $0.02 per share (non-GAAP measure).

Mr. Duffner concluded, “We have made great strides increasing shipments, reducing expenses, and building our cash position in the first half of 2010. The emphasis on building our core business has helped eliminate incremental costs associated with our weight management brand FORZE GPS™ from a year ago. The Company has also reduced inventory levels and G&A costs, allowing us to build our cash position and to show positive financial results from a year ago.”

About the Company:

PacificHealth Laboratories, Inc. is an innovative and leading sports nutrition company that focuses on marketing, developing, and selling premium nutrition products to active consumers seeking to improve their health and performance. Our brands and nutrition tools consist of three discreet platforms: rehydration/energy, recovery, and optimal racing weight and include ForzeGPS, the first scientifically proven appetite management tool created specifically for athletes. To learn more, visit www.pacifichealthlabs.com.

This press release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects", "plans", "will", "estimates", "forecasts", "projects" or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.

SELECTED FINANCIAL DATA:

    PACIFICHEALTH LABORATORIES, INC. STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2010 AND 2009 (UNAUDITED)             Three Months Six Months Ended June 30, Ended June 30,

2010

2009

2010

2009

Revenue: Net product sales $ 2,554,306 $ 2,725,055 $ 4,204,571 $ 4,420,673   Cost of goods sold   1,336,291     1,439,471     2,245,670     2,393,468     Gross profit   1,218,015     1,285,584     1,958,901     2,027,205     Operating expenses: Sales and marketing 349,262 454,904 584,347 771,012 General and administrative   734,443     819,019     1,508,593     1,651,501     1,083,705     1,273,923     2,092,940     2,422,513    

Income (loss) before other income (expense) and

  provision for income taxes

  134,310     11,661     (134,039 )   (395,308 )   Other income (expense): Other income 4,000 4,000 4,000 4,000 Interest income 277 811 505 3,102 Interest expense   (1,862 )   (1,470 )   (2,971 )   (2,257 )   2,415     3,341     1,534     4,845     Income (loss) before provision for income taxes 136,725 15,002 (132,505 ) (390,463 )   Provision for income taxes   -     2,080     -     2,080     Net income (loss) $ 136,725   $ 12,922   $ (132,505 ) $ (392,543 )   Net income (loss) per common share - basic and diluted $ 0.01   $ 0.00   $ (0.01 ) $ (0.03 )   Weighted average shares outstanding - basic   16,039,606     14,680,710     15,862,791     14,570,712     Weighted average shares outstanding - diluted   16,039,606     14,858,810     15,862,791     14,570,712       PACIFICHEALTH LABORATORIES, INC. BALANCE SHEETS       ASSETS June 30, December 31, 2010 2009 (Unaudited)   Current assets: Cash and cash equivalents $ 606,808 $ 281,159 Other short-term investments 150,000 175,000 Accounts receivable, net 839,875 763,288 Inventories, net 615,525 806,212 Prepaid expenses 145,804 92,702 Tax loss receivable   -     303,931   Total current assets 2,358,012 2,422,292   Property and equipment, net 63,687 110,904   Deposits   10,895     10,895     Total assets $ 2,432,594   $ 2,544,091     LIABILITIES AND STOCKHOLDERS' EQUITY   Current liabilities: Line of credit $ 75,000 $ - Notes payable 62,672 12,182 Accounts payable and accrued expenses 1,087,833 1,042,051 Deferred revenue   67,081     306,239   Total current liabilities   1,292,586     1,360,472     Commitments   Stockholders' equity: Common stock, $.0025 par value; authorized 50,000,000 shares; issued and outstanding: 16,365,257 and 15,624,017 shares, respectively 40,913 39,060 Additional paid-in capital 20,118,640 20,031,599 Accumulated deficit   (19,019,545 )   (18,887,040 )   1,140,008     1,183,619     Total liabilities and stockholders' equity $ 2,432,594   $ 2,544,091